Please login to the form below

Not currently logged in
Email:
Password:

Pfizer strengthens board of directors

Ronald Blaylock brings financial and business leadership expertise

Pfizer Ronald BlaylockPfizer has bolstered its board of directors with the appointment of Ronald Blaylock, who joins with immediate effect.

Blaylock currently serves as managing partner of private equity firm GenNx360 Capital Partners, which he founded in 2006.

Prior to this, he founded investment banking firm Blaylock & Company in 1993, subsequently serving as chairman and chief executive officer.

He brings further senior management experience from Paine Webber and CitiGroup, and currently serves on the boards of CarMax, Radio One, WR Berkley and Syncreon.

Ian Read, Pfizer's chairman and chief executive officer, said: “We are pleased to welcome Ron Blaylock to Pfizer's board of directors.

“He brings business, financial and leadership expertise, which will be an asset to Pfizer's diverse board and to our company. The addition of Ron to our board helps to ensure that Pfizer continues to benefit from a breadth and variety of experience.”

28th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Digital
Tools for the digital world
The next step for the pharma industry...
How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...

Infographics